Siirry pääsisältöön
Käyttämääsi selainta ei enää tueta – lue lisää.
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
2025 Q2 -tulosraportti
227 päivää sitten

Tarjoustasot

NorwayOslo Børs
Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
388--
4 612--
165--
6--
269--

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2025 Q4 -tulosraportti
15.4.

2 päivää

Menneet tapahtumat
2025 Q2 -tulosraportti
28.8.2025
2024 Q4 -tulosraportti
10.4.2025
2024 Q2 -tulosraportti
29.8.2024
2023 Q4 -tulosraportti
25.4.2024
2023 Q3 -tulosraportti
9.11.2023

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
  • 2 t sitten
    ·
    2 t sitten
    ·
    Could there be a real downturn tomorrow after an “anti-climax” announcement about missteps from management's side, or can people overlook it? No matter what, it's win-win for me personally, so more can be bought before the concert on the 27th.😊
    4 min sitten · Muokattu
    4 min sitten · Muokattu
    There is still annual report coming this week wednesday. After that we can start waiting for new target prices from Analyst group "We will return with an updated equity research report of Circio following the FY2025 report". This week is going to be good for price, even without abstracts. Edit: If there is still that short open when new target prices come, only way out for Qube is to pay asking price. My guess is by end of week there is increase ln value and someone gets fired at Qube's office for shorting Circio.
  • 4 t sitten
    ·
    4 t sitten
    ·
    The abstracts come 27 April see Circio's website.
    2 t sitten
    ·
    2 t sitten
    ·
    Exactly, with reference to Circio. That is only done if it is true.
  • 4 t sitten
    ·
    4 t sitten
    ·
    A 2.0 version of a previous speculative prediction.. Who could the Big Pharma partner be? (feasibility study since November) And how well would circVec fit into their current programs? #Pfizer: Relevant programs: Hemophilia A/B gene therapy (AAV-based) Several internal programs via acquisitions (e.g. Bamboo Therapeutics) Known problems in the field: High dose = liver toxicity Variable effect over time Immune response to AAV Where circVec fits perfectly: Lower dose = less toxicity More stable expression = better durability Timing-fit: VERY high Pfizer is directly facing problems circVec tries to solve #Roche Relevant programs: Spark Therapeutics (acquired by Roche) Eye gene therapy (AAV) — one of the most mature areas Known problems: Limited expression in retina Dose constraints (the eye is sensitive) circVec edge: Circio has eye-data with 50x expression It is directly applicable in the Roche/Spark pipeline Timing-fit: EXTREMELY high “almost too perfect” #AstraZeneca Relevant programs: Quietly building gene therapy pipeline Focus on cardio + rare diseases Situation: Still in building phase Fewer mature AAV-assets circVec role: Can be used early in pipeline design Not necessarily as a “fix”, but as a “design choice” Timing-fit: MEDIUM More forward-looking than problem-solving #Eli Lilly Relevant programs: Eli Lilly recently acquired ORNA Therapeutics which also works with circRNA. Classic Big Pharma strategy: “let multiple technologies compete internally” Situation: Less mature AAV pipeline than Pfizer/Roche Still in strategy/building phase However, constantly and aggressively looking for new tech. circVec role: Exploratory tech scouting Timing-fit: MEDIUM
    27 min sitten
    ·
    27 min sitten
    ·
    Moderna may be the fifth candidate
  • 4 t sitten
    ·
    4 t sitten
    ·
    Circio is in the process of moving from research phase to commercial visibility, a point where biotech is historically significantly re-priced. The platform technology provides both scalability and attractive partner potential, while the market still prices the case conservatively. With several upcoming triggers and increasing attention, I believe there are good conditions for a rapid re-pricing. My assessment is clear: The probability of a doubling from today's level within a relatively short time appears high given the current position and momentum. Fundamental conditions are strengthening, the market is lagging. This is typically the phase where the largest movements occur.
  • 5 t sitten
    ·
    5 t sitten
    ·
    Let me hear your thoughts on tomorrow, and 12-24 months out :)
    4 t sitten
    ·
    4 t sitten
    ·
    Tomorrow is a non-event, but also the countdown to something big. As Raketmanden mentions, it's now time for gardening and rosé wine, and in 24 months you can look at your gardener, while the Pingus PSI is poured into the glass by the butler. Pingus is also originally Danish, so just fill up!
    1 t sitten
    ·
    1 t sitten
    ·
    And then the question is, have you spotted the next stock, without having to discuss anything other than Circio here.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Tuotteita joiden kohde-etuutena tämä arvopaperi

2025 Q2 -tulosraportti
227 päivää sitten

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
  • 2 t sitten
    ·
    2 t sitten
    ·
    Could there be a real downturn tomorrow after an “anti-climax” announcement about missteps from management's side, or can people overlook it? No matter what, it's win-win for me personally, so more can be bought before the concert on the 27th.😊
    4 min sitten · Muokattu
    4 min sitten · Muokattu
    There is still annual report coming this week wednesday. After that we can start waiting for new target prices from Analyst group "We will return with an updated equity research report of Circio following the FY2025 report". This week is going to be good for price, even without abstracts. Edit: If there is still that short open when new target prices come, only way out for Qube is to pay asking price. My guess is by end of week there is increase ln value and someone gets fired at Qube's office for shorting Circio.
  • 4 t sitten
    ·
    4 t sitten
    ·
    The abstracts come 27 April see Circio's website.
    2 t sitten
    ·
    2 t sitten
    ·
    Exactly, with reference to Circio. That is only done if it is true.
  • 4 t sitten
    ·
    4 t sitten
    ·
    A 2.0 version of a previous speculative prediction.. Who could the Big Pharma partner be? (feasibility study since November) And how well would circVec fit into their current programs? #Pfizer: Relevant programs: Hemophilia A/B gene therapy (AAV-based) Several internal programs via acquisitions (e.g. Bamboo Therapeutics) Known problems in the field: High dose = liver toxicity Variable effect over time Immune response to AAV Where circVec fits perfectly: Lower dose = less toxicity More stable expression = better durability Timing-fit: VERY high Pfizer is directly facing problems circVec tries to solve #Roche Relevant programs: Spark Therapeutics (acquired by Roche) Eye gene therapy (AAV) — one of the most mature areas Known problems: Limited expression in retina Dose constraints (the eye is sensitive) circVec edge: Circio has eye-data with 50x expression It is directly applicable in the Roche/Spark pipeline Timing-fit: EXTREMELY high “almost too perfect” #AstraZeneca Relevant programs: Quietly building gene therapy pipeline Focus on cardio + rare diseases Situation: Still in building phase Fewer mature AAV-assets circVec role: Can be used early in pipeline design Not necessarily as a “fix”, but as a “design choice” Timing-fit: MEDIUM More forward-looking than problem-solving #Eli Lilly Relevant programs: Eli Lilly recently acquired ORNA Therapeutics which also works with circRNA. Classic Big Pharma strategy: “let multiple technologies compete internally” Situation: Less mature AAV pipeline than Pfizer/Roche Still in strategy/building phase However, constantly and aggressively looking for new tech. circVec role: Exploratory tech scouting Timing-fit: MEDIUM
    27 min sitten
    ·
    27 min sitten
    ·
    Moderna may be the fifth candidate
  • 4 t sitten
    ·
    4 t sitten
    ·
    Circio is in the process of moving from research phase to commercial visibility, a point where biotech is historically significantly re-priced. The platform technology provides both scalability and attractive partner potential, while the market still prices the case conservatively. With several upcoming triggers and increasing attention, I believe there are good conditions for a rapid re-pricing. My assessment is clear: The probability of a doubling from today's level within a relatively short time appears high given the current position and momentum. Fundamental conditions are strengthening, the market is lagging. This is typically the phase where the largest movements occur.
  • 5 t sitten
    ·
    5 t sitten
    ·
    Let me hear your thoughts on tomorrow, and 12-24 months out :)
    4 t sitten
    ·
    4 t sitten
    ·
    Tomorrow is a non-event, but also the countdown to something big. As Raketmanden mentions, it's now time for gardening and rosé wine, and in 24 months you can look at your gardener, while the Pingus PSI is poured into the glass by the butler. Pingus is also originally Danish, so just fill up!
    1 t sitten
    ·
    1 t sitten
    ·
    And then the question is, have you spotted the next stock, without having to discuss anything other than Circio here.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

NorwayOslo Børs
Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
388--
4 612--
165--
6--
269--

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2025 Q4 -tulosraportti
15.4.

2 päivää

Menneet tapahtumat
2025 Q2 -tulosraportti
28.8.2025
2024 Q4 -tulosraportti
10.4.2025
2024 Q2 -tulosraportti
29.8.2024
2023 Q4 -tulosraportti
25.4.2024
2023 Q3 -tulosraportti
9.11.2023

Tuotteita joiden kohde-etuutena tämä arvopaperi

2025 Q2 -tulosraportti
227 päivää sitten

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2025 Q4 -tulosraportti
15.4.

2 päivää

Menneet tapahtumat
2025 Q2 -tulosraportti
28.8.2025
2024 Q4 -tulosraportti
10.4.2025
2024 Q2 -tulosraportti
29.8.2024
2023 Q4 -tulosraportti
25.4.2024
2023 Q3 -tulosraportti
9.11.2023

Tuotteita joiden kohde-etuutena tämä arvopaperi

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
  • 2 t sitten
    ·
    2 t sitten
    ·
    Could there be a real downturn tomorrow after an “anti-climax” announcement about missteps from management's side, or can people overlook it? No matter what, it's win-win for me personally, so more can be bought before the concert on the 27th.😊
    4 min sitten · Muokattu
    4 min sitten · Muokattu
    There is still annual report coming this week wednesday. After that we can start waiting for new target prices from Analyst group "We will return with an updated equity research report of Circio following the FY2025 report". This week is going to be good for price, even without abstracts. Edit: If there is still that short open when new target prices come, only way out for Qube is to pay asking price. My guess is by end of week there is increase ln value and someone gets fired at Qube's office for shorting Circio.
  • 4 t sitten
    ·
    4 t sitten
    ·
    The abstracts come 27 April see Circio's website.
    2 t sitten
    ·
    2 t sitten
    ·
    Exactly, with reference to Circio. That is only done if it is true.
  • 4 t sitten
    ·
    4 t sitten
    ·
    A 2.0 version of a previous speculative prediction.. Who could the Big Pharma partner be? (feasibility study since November) And how well would circVec fit into their current programs? #Pfizer: Relevant programs: Hemophilia A/B gene therapy (AAV-based) Several internal programs via acquisitions (e.g. Bamboo Therapeutics) Known problems in the field: High dose = liver toxicity Variable effect over time Immune response to AAV Where circVec fits perfectly: Lower dose = less toxicity More stable expression = better durability Timing-fit: VERY high Pfizer is directly facing problems circVec tries to solve #Roche Relevant programs: Spark Therapeutics (acquired by Roche) Eye gene therapy (AAV) — one of the most mature areas Known problems: Limited expression in retina Dose constraints (the eye is sensitive) circVec edge: Circio has eye-data with 50x expression It is directly applicable in the Roche/Spark pipeline Timing-fit: EXTREMELY high “almost too perfect” #AstraZeneca Relevant programs: Quietly building gene therapy pipeline Focus on cardio + rare diseases Situation: Still in building phase Fewer mature AAV-assets circVec role: Can be used early in pipeline design Not necessarily as a “fix”, but as a “design choice” Timing-fit: MEDIUM More forward-looking than problem-solving #Eli Lilly Relevant programs: Eli Lilly recently acquired ORNA Therapeutics which also works with circRNA. Classic Big Pharma strategy: “let multiple technologies compete internally” Situation: Less mature AAV pipeline than Pfizer/Roche Still in strategy/building phase However, constantly and aggressively looking for new tech. circVec role: Exploratory tech scouting Timing-fit: MEDIUM
    27 min sitten
    ·
    27 min sitten
    ·
    Moderna may be the fifth candidate
  • 4 t sitten
    ·
    4 t sitten
    ·
    Circio is in the process of moving from research phase to commercial visibility, a point where biotech is historically significantly re-priced. The platform technology provides both scalability and attractive partner potential, while the market still prices the case conservatively. With several upcoming triggers and increasing attention, I believe there are good conditions for a rapid re-pricing. My assessment is clear: The probability of a doubling from today's level within a relatively short time appears high given the current position and momentum. Fundamental conditions are strengthening, the market is lagging. This is typically the phase where the largest movements occur.
  • 5 t sitten
    ·
    5 t sitten
    ·
    Let me hear your thoughts on tomorrow, and 12-24 months out :)
    4 t sitten
    ·
    4 t sitten
    ·
    Tomorrow is a non-event, but also the countdown to something big. As Raketmanden mentions, it's now time for gardening and rosé wine, and in 24 months you can look at your gardener, while the Pingus PSI is poured into the glass by the butler. Pingus is also originally Danish, so just fill up!
    1 t sitten
    ·
    1 t sitten
    ·
    And then the question is, have you spotted the next stock, without having to discuss anything other than Circio here.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

NorwayOslo Børs
Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
388--
4 612--
165--
6--
269--

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt
© 2026 Nordnet Bank AB.
Nordnet | Alvar Aallon katu 5 C, 3. krs | FI-00100 Helsinki